What Dose of Ponatinib Is Both Safe and Effective to Treat CML?
Автор: CheckRare
Загружено: 2020-06-03
Просмотров: 189
Описание:
Jorge Cortes, MD from the Georgia Cancer Center at Augusta University discusses interim data presented at the ASCO 2020 conference. The data comes from the open label phase II OPTIC study testing different dosages of ponatinib to treat chronic phase chronic myeloid leukemia (CML).
Ponatinib was approved for treatment of chronic phase-CML however, due to evidence of possibly toxicity, more research is being done on the drug’s side effects. Interim data suggests that response-based dosing regimens reduce the drug’s risks.
CML is a rare blood cancer characterized by the unregulated growth of myeloid cells in the bone marrow and their accumulation in the blood. Approximately 15% of new leukemia cases are CML. Each year, there are about 8,450 new cases of CML in the United States and 1,130 will die of CML. Numerous treatments are available for this condition and even more are in development.
To learn more about CML and other rare cancers, visit checkrare.com/diseases/cancers/
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
